The study of precision medicine is flourishing in recent decades. Tumor-agnostic therapy is one of the targeted therapies, which can treat the malignant cells regardless of where they grow. Herein we reviewed currently the U.S. FDA-approved tumor-agnostic therapies: one monoclonal antibody as a PD-1 inhibitor called pembrolizumab and four small-molecule kinase inhibitors, larotrectinib, entrectinib, selpercatinib, and pralsetinib. We also summarized the reported synthetic routes toward three drugs and some developing candidates under clinical trials as tumor-agnostic therapy.
All Science Journal Classification (ASJC) codes